Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

RAC-alpha serine/threonine-protein kinase (EC (Protein kinase B) (PKB) (Protein kinase B alpha) (PKB alpha) (RAC-PK-alpha)

 AKT1_RAT                Reviewed;         480 AA.
01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
01-FEB-1996, sequence version 1.
13-FEB-2019, entry version 195.
RecName: Full=RAC-alpha serine/threonine-protein kinase;
AltName: Full=Protein kinase B;
AltName: Full=Protein kinase B alpha;
Short=PKB alpha;
AltName: Full=RAC-PK-alpha;
Rattus norvegicus (Rat).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha;
Muroidea; Muridae; Murinae; Rattus.
PubMed=7999118; DOI=10.1006/bbrc.1994.2738;
Konishi H., Shinomura T., Kuroda S.I., Ono Y., Kikkawa U.;
"Molecular cloning of rat RAC protein kinase alpha and beta and their
association with protein kinase C zeta.";
Biochem. Biophys. Res. Commun. 205:817-825(1994).
PubMed=9632753; DOI=10.1128/MCB.18.7.3708;
Kitamura T., Ogawa W., Sakaue H., Hino Y., Kuroda S., Takata M.,
Matsumoto M., Maeda T., Konishi H., Kikkawa U., Kasuga M.;
"Requirement for activation of the serine-threonine kinase Akt
(protein kinase B) in insulin stimulation of protein synthesis but not
of glucose transport.";
Mol. Cell. Biol. 18:3708-3717(1998).
LYS-179; THR-308 AND SER-473.
PubMed=10400692; DOI=10.1074/jbc.274.29.20611;
Takata M., Ogawa W., Kitamura T., Hino Y., Kuroda S., Kotani K.,
Klip A., Gingras A.-C., Sonenberg N., Kasuga M.;
"Requirement for Akt (protein kinase B) in insulin-induced activation
of glycogen synthase and phosphorylation of 4E-BP1 (PHAS-1).";
J. Biol. Chem. 274:20611-20618(1999).
PubMed=11882383; DOI=10.1016/S0898-6568(01)00271-6;
Nicholson K.M., Anderson N.G.;
"The protein kinase B/Akt signalling pathway in human malignancy.";
Cell. Signal. 14:381-395(2002).
PubMed=12107176; DOI=10.1074/jbc.M204681200;
Berwick D.C., Hers I., Heesom K.J., Moule S.K., Tavare J.M.;
"The identification of ATP-citrate lyase as a protein kinase B (Akt)
substrate in primary adipocytes.";
J. Biol. Chem. 277:33895-33900(2002).
PubMed=15546921; DOI=10.1242/jcs.01517;
Berwick D.C., Dell G.C., Welsh G.I., Heesom K.J., Hers I.,
Fletcher L.M., Cooke F.T., Tavare J.M.;
"Protein kinase B phosphorylation of PIKfyve regulates the trafficking
of GLUT4 vesicles.";
J. Cell Sci. 117:5985-5993(2004).
PubMed=16832058; DOI=10.1073/pnas.0602923103;
Liu Z., Ahn J.Y., Liu X., Ye K.;
"Ebp1 isoforms distinctively regulate cell survival and
Proc. Natl. Acad. Sci. U.S.A. 103:10917-10922(2006).
PubMed=21620960; DOI=10.1016/j.cellsig.2011.05.004;
Hers I., Vincent E.E., Tavare J.M.;
"Akt signalling in health and disease.";
Cell. Signal. 23:1515-1527(2011).
PubMed=21432781; DOI=10.14670/HH-26.651;
Heron-Milhavet L., Khouya N., Fernandez A., Lamb N.J.;
"Akt1 and Akt2: differentiating the aktion.";
Histol. Histopathol. 26:651-662(2011).
PubMed=22673903; DOI=10.1038/ncomms1871;
Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A.,
Lundby C., Olsen J.V.;
"Quantitative maps of protein phosphorylation sites across 14
different rat organs and tissues.";
Nat. Commun. 3:876-876(2012).
-!- FUNCTION: AKT1 is one of 3 closely related serine/threonine-
protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and
which regulate many processes including metabolism, proliferation,
cell survival, growth and angiogenesis. This is mediated through
serine and/or threonine phosphorylation of a range of downstream
substrates. Over 100 substrate candidates have been reported so
far, but for most of them, no isoform specificity has been
reported. AKT is responsible of the regulation of glucose uptake
by mediating insulin-induced translocation of the SLC2A4/GLUT4
glucose transporter to the cell surface. Phosphorylation of PTPN1
at 'Ser-50' negatively modulates its phosphatase activity
preventing dephosphorylation of the insulin receptor and the
attenuation of insulin signaling. Phosphorylation of TBC1D4
triggers the binding of this effector to inhibitory 14-3-3
proteins, which is required for insulin-stimulated glucose
transport. AKT regulates also the storage of glucose in the form
of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at
'Ser-9', resulting in inhibition of its kinase activity.
Phosphorylation of GSK3 isoforms by AKT is also thought to be one
mechanism by which cell proliferation is driven. AKT regulates
also cell survival via the phosphorylation of MAP3K5 (apoptosis
signal-related kinase). Phosphorylation of 'Ser-83' decreases
MAP3K5 kinase activity stimulated by oxidative stress and thereby
prevents apoptosis. AKT mediates insulin-stimulated protein
synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462',
thereby activating mTORC1 signaling and leading to both
phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is
involved in the phosphorylation of members of the FOXO factors
(Forkhead family of transcription factors), leading to binding of
14-3-3 proteins and cytoplasmic localization. In particular, FOXO1
is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and
FOXO4 are phosphorylated on equivalent sites. AKT has an important
role in the regulation of NF-kappa-B-dependent gene transcription
and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-
response element binding protein). The phosphorylation of CREB1
induces the binding of accessory proteins that are necessary for
the transcription of pro-survival genes such as BCL2 and MCL1. AKT
phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby
potentially regulating ACLY activity and fatty acid synthesis.
Activates the 3B isoform of cyclic nucleotide phosphodiesterase
(PDE3B) via phosphorylation of 'Ser-273', resulting in reduced
cyclic AMP levels and inhibition of lipolysis. Phosphorylates
PIKFYVE on 'Ser-318', which results in increased PI(3)P-5
activity. The Rho GTPase-activating protein DLC1 is another
substrate and its phosphorylation is implicated in the regulation
cell proliferation and cell growth. AKT plays a role as key
modulator of the AKT-mTOR signaling pathway controlling the tempo
of the process of newborn neurons integration during adult
neurogenesis, including correct neuron positioning, dendritic
development and synapse formation. Signals downstream of
phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of
various growth factors such as platelet-derived growth factor
(PDGF), epidermal growth factor (EGF), insulin and insulin-like
growth factor I (IGF-I). AKT mediates the antiapoptotic effects of
IGF-I. Essential for the SPATA13-mediated regulation of cell
migration and adhesion assembly and disassembly. May be involved
in the regulation of the placental development. Phosphorylates
STK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its:
kinase activity, nuclear translocation, autophosphorylation and
ability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr-
117' and 'Thr-384' leading to inhibition of its: cleavage, kinase
activity, autophosphorylation at Thr-180, binding to RASSF1 and
nuclear translocation. Phosphorylates SRPK2 and enhances its
kinase activity towards SRSF2 and ACIN1 and promotes its nuclear
translocation (By similarity). Phosphorylates RAF1 at 'Ser-259'
and negatively regulates its activity. Phosphorylation of BAD
stimulates its pro-apoptotic activity (By similarity).
Phosphorylates KAT6A at 'Thr-369' and this phosphorylation
inhibits the interaction of KAT6A with PML and negatively
regulates its acetylation activity towards p53/TP53 (By
similarity). {ECO:0000250}.
-!- FUNCTION: AKT1-specific substrates have been recently identified,
including palladin (PALLD), which phosphorylation modulates
cytoskeletal organization and cell motility; prohibitin (PHB),
playing an important role in cell metabolism and proliferation;
and CDKN1A, for which phosphorylation at 'Thr-145' induces its
release from CDK2 and cytoplasmic relocalization. These recent
findings indicate that the AKT1 isoform has a more specific role
in cell motility and proliferation. Phosphorylates CLK2 thereby
controlling cell survival to ionizing radiation.
{ECO:0000269|PubMed:10400692, ECO:0000269|PubMed:12107176,
ECO:0000269|PubMed:15546921, ECO:0000269|PubMed:9632753}.
Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
[protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999,
ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, ChEBI:CHEBI:456216;
Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
-!- ACTIVITY REGULATION: Three specific sites, one in the kinase
domain (Thr-308) and the two other ones in the C-terminal
regulatory region (Ser-473 and Tyr-474), need to be phosphorylated
for its full activation.
-!- SUBUNIT: Interacts (via the C-terminus) with CCDC88A (via its C-
terminus). Interacts with GRB10; the interaction leads to GRB10
phosphorylation thus promoting YWHAE-binding. Interacts with AGAP2
(isoform 2/PIKE-A); the interaction occurs in the presence of
guanine nucleotides. Interacts with AKTIP. Interacts (via PH
domain) with MTCP1, TCL1A AND TCL1B. Interacts with CDKN1B; the
interaction phosphorylates CDKN1B promoting 14-3-3 binding and
cell-cycle progression. Interacts with MAP3K5 and TRAF6. Interacts
with BAD, PPP2R5B, STK3 and STK4. Interacts (via PH domain) with
SIRT1. Interacts with SRPK2 in a phosphorylation-dependent manner.
Interacts with TNK2 and CLK2. Interacts with RAF1. Interacts (via
the C-terminus) with THEM4 (via its C-terminus). Interacts with
TRIM13; the interaction ubiquitinates AKT1 leading to its
proteasomal degradation. Interacts with and phosphorylated by
PDPK1 (By similarity). Interacts with BTBD10 (By similarity).
Interacts with KCTD20 (By similarity). Interacts with PA2G4.
Interacts with KIF14; the interaction is detected in the plasma
membrane upon INS stimulation and promotes AKT1 phosphorylation
(By similarity). Interacts with FAM83B; activates the PI3K/AKT
signaling cascade (By similarity). Interacts with WDFY2 (via WD
repeats 1-3) (By similarity). Forms a complex with WDFY2 and FOXO1
(By similarity). Interacts with FAM168A (By similarity). Interacts
with SYAP1 (via phosphorylated form and BSD domain); this
interaction is enhanced in a mTORC2-mediated manner in response to
epidermal growth factor (EGF) stimulation and activates AKT1 (By
similarity). Interacts with PKHM3 (By similarity).
{ECO:0000250|UniProtKB:P31749, ECO:0000250|UniProtKB:P31750,
P04797:Gapdh; NbExp=3; IntAct=EBI-7204362, EBI-349219;
Q63369:Nfkb1; NbExp=9; IntAct=EBI-7204362, EBI-8498561;
O70436:Smad2; NbExp=2; IntAct=EBI-7204362, EBI-7948047;
P84025:Smad3; NbExp=4; IntAct=EBI-7204362, EBI-7201857;
-!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P31750}.
Nucleus {ECO:0000250|UniProtKB:P31750}. Cell membrane
{ECO:0000250|UniProtKB:P31750}. Note=Nucleus after activation by
integrin-linked protein kinase 1 (ILK1). Nuclear translocation is
enhanced by interaction with TCL1A (By similarity).
Phosphorylation on Tyr-176 by TNK2 results in its localization to
the cell membrane where it is targeted for further
phosphorylations on Thr-308 and Ser-473 leading to its activation
and the activated form translocates to the nucleus. Colocalizes
with WDFY2 in intracellular vesicles (By similarity).
-!- TISSUE SPECIFICITY: Widely expressed. Low levels found in liver
with slightly higher levels present in thymus and testis.
-!- DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5-
trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-
kinase alpha (PIK3CA) activity results in its targeting to the
plasma membrane. The PH domain mediates interaction with TNK2 and
Tyr-176 is also essential for this interaction (By similarity).
-!- DOMAIN: The AGC-kinase C-terminal mediates interaction with THEM4.
-!- PTM: O-GlcNAcylation at Thr-305 and Thr-312 inhibits activating
phosphorylation at Thr-308 via disrupting the interaction between
AKT1 and PDPK1. O-GlcNAcylation at Ser-473 also probably
interferes with phosphorylation at this site.
-!- PTM: Phosphorylation on Thr-308, Ser-473 and Tyr-474 is required
for full activity. Activated TNK2 phosphorylates it on Tyr-176
resulting in its binding to the anionic plasma membrane
phospholipid PA. This phosphorylated form localizes to the cell
membrane, where it is targeted by PDPK1 and PDPK2 for further
phosphorylations on Thr-308 and Ser-473 leading to its activation.
Ser-473 phosphorylation by mTORC2 favors Thr-308 phosphorylation
by PDPK1. Phosphorylated at Thr-308 and Ser-473 by IKBKE and TBK1
(By similarity). Ser-473 phosphorylation is enhanced by signaling
through activated FLT3 (By similarity). Dephosphorylated at Thr-
308 and Ser-473 by PP2A phosphatase. The phosphorylated form of
PPP2R5B is required for bridging AKT1 with PP2A phosphatase. Ser-
473 is dephosphorylated by CPPED1, leading to termination of
signaling (By similarity). {ECO:0000250}.
-!- PTM: Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked
polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1
ubiquitination is critical for phosphorylation and activation.
When ubiquitinated, it translocates to the plasma membrane, where
it becomes phosphorylated. When fully phosphorylated and
translocated into the nucleus, undergoes 'Lys-48'-
polyubiquitination catalyzed by TTC3, leading to its degradation
by the proteasome. Ubiquitinated via 'Lys-48'-linked
polyubiquitination by ZNRF1, leading to its degradation by the
proteasome. Also ubiquitinated by TRIM13 leading to its
proteasomal degradation. Phosphorylated, undergoes 'Lys-48'-linked
polyubiquitination preferentially at Lys-284 catalyzed by MUL1,
leading to its proteasomal degradation (By similarity).
-!- PTM: Acetylated on Lys-14 and Lys-20 by the histone
acetyltransferases EP300 and KAT2B. Acetylation results in reduced
phosphorylation and inhibition of activity. Deacetylated at Lys-14
and Lys-20 by SIRT1. SIRT1-mediated deacetylation relieves the
inhibition (By similarity). {ECO:0000250}.
-!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
protein kinase family. RAC subfamily. {ECO:0000305}.
-!- CAUTION: In light of strong homologies in the primary amino acid
sequence, the 3 AKT kinases were long surmised to play redundant
and overlapping roles. More recent studies has brought into
question the redundancy within AKT kinase isoforms and instead
pointed to isoform specific functions in different cellular events
and diseases. AKT1 is more specifically involved in cellular
survival pathways, by inhibiting apoptotic processes; whereas AKT2
is more specific for the insulin receptor signaling pathway.
Moreover, while AKT1 and AKT2 are often implicated in many aspects
of cellular transformation, the 2 isoforms act in a complementary
opposing manner. The role of AKT3 is less clear, though it appears
to be predominantly expressed in brain. {ECO:0000305}.
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
EMBL; D30040; BAA06279.1; -; mRNA.
PIR; JC2437; JC2437.
RefSeq; NP_150233.1; NM_033230.2.
RefSeq; XP_006240693.1; XM_006240631.2.
UniGene; Rn.11422; -.
ProteinModelPortal; P47196; -.
SMR; P47196; -.
BioGrid; 246375; 13.
DIP; DIP-42185N; -.
IntAct; P47196; 10.
MINT; P47196; -.
STRING; 10116.ENSRNOP00000038369; -.
ChEMBL; CHEMBL1075215; -.
iPTMnet; P47196; -.
PhosphoSitePlus; P47196; -.
jPOST; P47196; -.
PaxDb; P47196; -.
PRIDE; P47196; -.
Ensembl; ENSRNOT00000031164; ENSRNOP00000038369; ENSRNOG00000028629.
GeneID; 24185; -.
KEGG; rno:24185; -.
UCSC; RGD:2081; rat.
CTD; 207; -.
RGD; 2081; Akt1.
eggNOG; KOG0598; Eukaryota.
GeneTree; ENSGT00940000158752; -.
HOGENOM; HOG000233033; -.
HOVERGEN; HBG108317; -.
InParanoid; P47196; -.
KO; K04456; -.
OrthoDB; 614710at2759; -.
PhylomeDB; P47196; -.
TreeFam; TF102004; -.
BRENDA;; 5301.
Reactome; R-RNO-1257604; PIP3 activates AKT signaling.
Reactome; R-RNO-1474151; Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation.
Reactome; R-RNO-165159; mTOR signalling.
Reactome; R-RNO-198323; AKT phosphorylates targets in the cytosol.
Reactome; R-RNO-198693; AKT phosphorylates targets in the nucleus.
Reactome; R-RNO-199418; Negative regulation of the PI3K/AKT network.
Reactome; R-RNO-203615; eNOS activation.
Reactome; R-RNO-354192; Integrin alphaIIb beta3 signaling.
Reactome; R-RNO-3769402; Deactivation of the beta-catenin transactivating complex.
Reactome; R-RNO-389357; CD28 dependent PI3K/Akt signaling.
Reactome; R-RNO-389513; CTLA4 inhibitory signaling.
Reactome; R-RNO-392451; G beta:gamma signalling through PI3Kgamma.
Reactome; R-RNO-450385; Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA.
Reactome; R-RNO-5218920; VEGFR2 mediated vascular permeability.
Reactome; R-RNO-6804757; Regulation of TP53 Degradation.
Reactome; R-RNO-6804758; Regulation of TP53 Activity through Acetylation.
Reactome; R-RNO-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
Reactome; R-RNO-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1.
PRO; PR:P47196; -.
Proteomes; UP000002494; Chromosome 6.
Bgee; ENSRNOG00000028629; Expressed in 10 organ(s), highest expression level in heart.
Genevisible; P47196; RN.
GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
GO; GO:0036064; C:ciliary basal body; IEA:Ensembl.
GO; GO:0005737; C:cytoplasm; IDA:RGD.
GO; GO:0005829; C:cytosol; IDA:RGD.
GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
GO; GO:0005634; C:nucleus; IDA:UniProtKB.
GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
GO; GO:0032991; C:protein-containing complex; IEA:Ensembl.
GO; GO:0005819; C:spindle; IEA:Ensembl.
GO; GO:0031982; C:vesicle; IEA:Ensembl.
GO; GO:0071889; F:14-3-3 protein binding; IEA:Ensembl.
GO; GO:0005524; F:ATP binding; IDA:RGD.
GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
GO; GO:0032794; F:GTPase activating protein binding; IPI:RGD.
GO; GO:0030235; F:nitric-oxide synthase regulator activity; IEA:Ensembl.
GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate binding; IEA:Ensembl.
GO; GO:0043325; F:phosphatidylinositol-3,4-bisphosphate binding; IEA:Ensembl.
GO; GO:0042803; F:protein homodimerization activity; IEA:Ensembl.
GO; GO:0004672; F:protein kinase activity; IDA:RGD.
GO; GO:0019901; F:protein kinase binding; IPI:RGD.
GO; GO:0005080; F:protein kinase C binding; IPI:RGD.
GO; GO:0051721; F:protein phosphatase 2A binding; IPI:RGD.
GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL.
GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:Ensembl.
GO; GO:0006924; P:activation-induced cell death of T cells; IEA:Ensembl.
GO; GO:0007568; P:aging; IDA:RGD.
GO; GO:0008637; P:apoptotic mitochondrial changes; IEA:Ensembl.
GO; GO:0008643; P:carbohydrate transport; IEA:UniProtKB-KW.
GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; IEA:Ensembl.
GO; GO:0030030; P:cell projection organization; IDA:MGI.
GO; GO:0071276; P:cellular response to cadmium ion; IEA:Ensembl.
GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl.
GO; GO:0097011; P:cellular response to granulocyte macrophage colony-stimulating factor stimulus; IEA:Ensembl.
GO; GO:0071456; P:cellular response to hypoxia; IDA:RGD.
GO; GO:0032869; P:cellular response to insulin stimulus; IMP:BHF-UCL.
GO; GO:0071260; P:cellular response to mechanical stimulus; IDA:RGD.
GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IDA:UniProtKB.
GO; GO:0071407; P:cellular response to organic cyclic compound; IDA:RGD.
GO; GO:0140052; P:cellular response to oxidised low-density lipoprotein particle stimulus; IEA:Ensembl.
GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEA:Ensembl.
GO; GO:0034614; P:cellular response to reactive oxygen species; IEA:Ensembl.
GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl.
GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IEA:Ensembl.
GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IEA:Ensembl.
GO; GO:0072655; P:establishment of protein localization to mitochondrion; IEA:Ensembl.
GO; GO:0097194; P:execution phase of apoptosis; IEA:Ensembl.
GO; GO:0007281; P:germ cell development; IEA:Ensembl.
GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl.
GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW.
GO; GO:0005978; P:glycogen biosynthetic process; IMP:UniProtKB.
GO; GO:0060709; P:glycogen cell differentiation involved in embryonic placenta development; IEA:Ensembl.
GO; GO:0030212; P:hyaluronan metabolic process; IEP:RGD.
GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
GO; GO:0008286; P:insulin receptor signaling pathway; IMP:UniProtKB.
GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; ISS:UniProtKB.
GO; GO:0035655; P:interleukin-18-mediated signaling pathway; IEA:Ensembl.
GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
GO; GO:0060716; P:labyrinthine layer blood vessel development; IEA:Ensembl.
GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl.
GO; GO:0072656; P:maintenance of protein location in mitochondrion; IEA:Ensembl.
GO; GO:0001893; P:maternal placenta development; IEA:Ensembl.
GO; GO:0043066; P:negative regulation of apoptotic process; TAS:RGD.
GO; GO:0010507; P:negative regulation of autophagy; IEA:Ensembl.
GO; GO:0045792; P:negative regulation of cell size; IDA:MGI.
GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; ISS:UniProtKB.
GO; GO:0031999; P:negative regulation of fatty acid beta-oxidation; IEA:Ensembl.
GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
GO; GO:0046329; P:negative regulation of JNK cascade; IDA:RGD.
GO; GO:1903038; P:negative regulation of leukocyte cell-cell adhesion; IEA:Ensembl.
GO; GO:0010748; P:negative regulation of long-chain fatty acid import across plasma membrane; IEA:Ensembl.
GO; GO:2000402; P:negative regulation of lymphocyte migration; IEA:Ensembl.
GO; GO:0032091; P:negative regulation of protein binding; IEA:Ensembl.
GO; GO:0006469; P:negative regulation of protein kinase activity; IDA:BHF-UCL.
GO; GO:0031397; P:negative regulation of protein ubiquitination; IEA:Ensembl.
GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; ISS:UniProtKB.
GO; GO:0038061; P:NIK/NF-kappaB signaling; IEA:Ensembl.
GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl.
GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
GO; GO:0018107; P:peptidyl-threonine phosphorylation; IEA:Ensembl.
GO; GO:0032287; P:peripheral nervous system myelin maintenance; IEA:Ensembl.
GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IEA:Ensembl.
GO; GO:0016310; P:phosphorylation; ISS:UniProtKB.
GO; GO:0043065; P:positive regulation of apoptotic process; IMP:RGD.
GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IEA:Ensembl.
GO; GO:0030307; P:positive regulation of cell growth; IDA:RGD.
GO; GO:0032270; P:positive regulation of cellular protein metabolic process; IMP:BHF-UCL.
GO; GO:0045737; P:positive regulation of cyclin-dependent protein serine/threonine kinase activity; IEA:Ensembl.
GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IEA:Ensembl.
GO; GO:0032079; P:positive regulation of endodeoxyribonuclease activity; IEA:Ensembl.
GO; GO:0001938; P:positive regulation of endothelial cell proliferation; ISS:UniProtKB.
GO; GO:0045600; P:positive regulation of fat cell differentiation; IEA:Ensembl.
GO; GO:0010763; P:positive regulation of fibroblast migration; IEA:Ensembl.
GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; IEA:Ensembl.
GO; GO:0046326; P:positive regulation of glucose import; IEA:Ensembl.
GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IEA:Ensembl.
GO; GO:1903721; P:positive regulation of I-kappaB phosphorylation; IEA:Ensembl.
GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IEA:Ensembl.
GO; GO:0010918; P:positive regulation of mitochondrial membrane potential; IEA:Ensembl.
GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IEA:Ensembl.
GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IEA:Ensembl.
GO; GO:0046622; P:positive regulation of organ growth; IEA:Ensembl.
GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IEA:Ensembl.
GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl.
GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl.
GO; GO:1900182; P:positive regulation of protein localization to nucleus; IEA:Ensembl.
GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IEA:Ensembl.
GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
GO; GO:0010765; P:positive regulation of sodium ion transport; IMP:MGI.
GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
GO; GO:0045907; P:positive regulation of vasoconstriction; IMP:RGD.
GO; GO:0030163; P:protein catabolic process; IEA:Ensembl.
GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl.
GO; GO:0043491; P:protein kinase B signaling; IEA:Ensembl.
GO; GO:0006468; P:protein phosphorylation; IDA:RGD.
GO; GO:0016567; P:protein ubiquitination; IEA:Ensembl.
GO; GO:0042981; P:regulation of apoptotic process; ISS:UniProtKB.
GO; GO:0030334; P:regulation of cell migration; IMP:RGD.
GO; GO:0031641; P:regulation of myelination; IEA:Ensembl.
GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB.
GO; GO:0032880; P:regulation of protein localization; IMP:MGI.
GO; GO:0006417; P:regulation of translation; IEA:UniProtKB-KW.
GO; GO:0034405; P:response to fluid shear stress; IEA:Ensembl.
GO; GO:0032094; P:response to food; IEA:Ensembl.
GO; GO:0060416; P:response to growth hormone; ISS:AgBase.
GO; GO:1990418; P:response to insulin-like growth factor stimulus; ISS:AgBase.
GO; GO:0006979; P:response to oxidative stress; ISS:ParkinsonsUK-UCL.
GO; GO:0070141; P:response to UV-A; IEA:Ensembl.
GO; GO:0007165; P:signal transduction; IDA:RGD.
GO; GO:0021510; P:spinal cord development; IDA:RGD.
GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl.
GO; GO:0006412; P:translation; IMP:UniProtKB.
CDD; cd01241; PH_PKB; 1.
CDD; cd05594; STKc_PKB_alpha; 1.
Gene3D;; -; 1.
InterPro; IPR000961; AGC-kinase_C.
InterPro; IPR034676; Akt1.
InterPro; IPR011009; Kinase-like_dom_sf.
InterPro; IPR011993; PH-like_dom_sf.
InterPro; IPR001849; PH_domain.
InterPro; IPR039026; PH_PKB.
InterPro; IPR017892; Pkinase_C.
InterPro; IPR000719; Prot_kinase_dom.
InterPro; IPR017441; Protein_kinase_ATP_BS.
InterPro; IPR039027; RAC_alpha/beta.
InterPro; IPR008271; Ser/Thr_kinase_AS.
PANTHER; PTHR24356:SF176; PTHR24356:SF176; 1.
Pfam; PF00169; PH; 1.
Pfam; PF00069; Pkinase; 1.
Pfam; PF00433; Pkinase_C; 1.
SMART; SM00233; PH; 1.
SMART; SM00133; S_TK_X; 1.
SMART; SM00220; S_TKc; 1.
SUPFAM; SSF56112; SSF56112; 1.
1: Evidence at protein level;
Acetylation; Apoptosis; ATP-binding; Carbohydrate metabolism;
Cell membrane; Complete proteome; Cytoplasm; Developmental protein;
Disulfide bond; Glucose metabolism; Glycogen biosynthesis;
Glycogen metabolism; Glycoprotein; Isopeptide bond; Kinase; Membrane;
Neurogenesis; Nucleotide-binding; Nucleus; Phosphoprotein;
Reference proteome; Serine/threonine-protein kinase; Sugar transport;
Transferase; Translation regulation; Transport; Ubl conjugation.
CHAIN 1 480 RAC-alpha serine/threonine-protein
DOMAIN 5 108 PH. {ECO:0000255|PROSITE-
DOMAIN 150 408 Protein kinase. {ECO:0000255|PROSITE-
DOMAIN 409 480 AGC-kinase C-terminal.
NP_BIND 156 164 ATP. {ECO:0000255|PROSITE-
REGION 14 19 Inositol-(1,3,4,5)-tetrakisphosphate
binding. {ECO:0000250}.
REGION 23 25 Inositol-(1,3,4,5)-tetrakisphosphate
binding. {ECO:0000250}.
REGION 228 230 Inhibitor binding. {ECO:0000250}.
ACT_SITE 274 274 Proton acceptor. {ECO:0000255|PROSITE-
ProRule:PRU00159, ECO:0000255|PROSITE-
BINDING 53 53 Inositol-(1,3,4,5)-tetrakisphosphate.
BINDING 86 86 Inositol-(1,3,4,5)-tetrakisphosphate.
BINDING 161 161 Inhibitor; via amide nitrogen.
BINDING 179 179 ATP.
BINDING 230 230 Inhibitor; via amide nitrogen.
BINDING 234 234 Inhibitor. {ECO:0000250}.
BINDING 292 292 Inhibitor. {ECO:0000250}.
MOD_RES 14 14 N6-acetyllysine.
MOD_RES 20 20 N6-acetyllysine.
MOD_RES 124 124 Phosphoserine.
MOD_RES 126 126 Phosphoserine; alternate.
MOD_RES 129 129 Phosphoserine; alternate.
MOD_RES 176 176 Phosphotyrosine; by TNK2.
MOD_RES 308 308 Phosphothreonine; by IKKE, PDPK1 and
TBK1. {ECO:0000250|UniProtKB:P31749}.
MOD_RES 448 448 Phosphothreonine.
MOD_RES 450 450 Phosphothreonine; by MTOR.
MOD_RES 473 473 Phosphoserine; by IKKE, MTOR and TBK1;
alternate. {ECO:0000305|PubMed:10400692}.
MOD_RES 474 474 Phosphotyrosine.
CARBOHYD 126 126 O-linked (GlcNAc) serine; alternate.
CARBOHYD 129 129 O-linked (GlcNAc) serine; alternate.
CARBOHYD 305 305 O-linked (GlcNAc) threonine.
CARBOHYD 312 312 O-linked (GlcNAc) threonine.
CARBOHYD 473 473 O-linked (GlcNAc) serine; alternate.
DISULFID 60 77 {ECO:0000250}.
DISULFID 296 310 {ECO:0000250}.
CROSSLNK 284 284 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in ubiquitin).
MUTAGEN 179 179 K->D: Lacks kinase activity. Inhibits
insulin-induced activation of glycogen
synthase when expressed.
MUTAGEN 308 308 T->A: Inhibits insulin-induced activation
of endogenous Akt1, insulin-stimulated
protein synthesis, insulin-induced
activation of glycogen synthase and
insulin-induced phosphorylation of 4E-BP1
in a dominant negative manner when
overexpressed; when associated with A-
473. {ECO:0000269|PubMed:10400692,
MUTAGEN 473 473 S->A: Inhibits insulin-induced activation
of endogenous Akt1, insulin-stimulated
protein synthesis, insulin-induced
activation of glycogen synthase and
insulin-induced phosphorylation of 4E-BP1
in a dominant negative manner when
overexpressed; when associated with A-
308. {ECO:0000269|PubMed:10400692,
SEQUENCE 480 AA; 55735 MW; 5DCAAE7134366D04 CRC64;

Related products :

Catalog number Product name Quantity
EIAAB31334 Bos taurus,Bovine,PKN,PKN1,PRK1,PRKCL1,Protein kinase C-like 1,Protein kinase C-like PKN,Protein kinase PKN-alpha,Protein-kinase C-related kinase 1,Serine_threonine-protein kinase N1,Serine-threonine
18-785-210337 p70 S6 Kinase (Phospho-Thr421) - EC; Ribosomal protein S6 kinase I; S6K; S6K1; 70 kDa ribosomal protein S6 kinase 1; p70 S6 kinase alpha; p70(S6K)-alpha; p70-S6K; P70S6K; p70-alpha Polyclonal 0.05 mg
18-785-210338 p70 S6 Kinase (Phospho-Ser411) - EC; Ribosomal protein S6 kinase I; S6K; S6K1; 70 kDa ribosomal protein S6 kinase 1; p70 S6 kinase alpha; p70(S6K)-alpha; p70-S6K; P70S6K; p70-alpha Polyclonal 0.05 mg
18-785-210338 p70 S6 Kinase (Phospho-Ser411) - EC; Ribosomal protein S6 kinase I; S6K; S6K1; 70 kDa ribosomal protein S6 kinase 1; p70 S6 kinase alpha; p70(S6K)-alpha; p70-S6K; P70S6K; p70-alpha Polyclonal 0.1 mg
18-785-210339 p70 S6 Kinase (Phospho-Ser424) - EC; Ribosomal protein S6 kinase I; S6K; S6K1; 70 kDa ribosomal protein S6 kinase 1; p70 S6 kinase alpha; p70(S6K)-alpha; p70-S6K; P70S6K; p70-alpha Polyclonal 0.05 mg
18-785-210339 p70 S6 Kinase (Phospho-Ser424) - EC; Ribosomal protein S6 kinase I; S6K; S6K1; 70 kDa ribosomal protein S6 kinase 1; p70 S6 kinase alpha; p70(S6K)-alpha; p70-S6K; P70S6K; p70-alpha Polyclonal 0.1 mg
18-785-210337 p70 S6 Kinase (Phospho-Thr421) - EC; Ribosomal protein S6 kinase I; S6K; S6K1; 70 kDa ribosomal protein S6 kinase 1; p70 S6 kinase alpha; p70(S6K)-alpha; p70-S6K; P70S6K; p70-alpha Polyclonal 0.1 mg
EIAAB25359 CDC42-binding protein kinase alpha,CDC42BPA,DMPK-like alpha,Homo sapiens,Human,KIAA0451,MRCK alpha,Myotonic dystrophy kinase-related CDC42-binding kinase alpha,Myotonic dystrophy protein kinase-like a
EIAAB31333 Homo sapiens,Human,PAK1,PAK-1,PKN,PKN1,PRK1,PRKCL1,Protease-activated kinase 1,Protein kinase C-like 1,Protein kinase C-like PKN,Protein kinase PKN-alpha,Protein-kinase C-related kinase 1,Serine_threo
EIAAB25358 CDC42-binding protein kinase alpha,Cdc42bpa,MRCK alpha,Myotonic dystrophy kinase-related CDC42-binding kinase alpha,Myotonic dystrophy protein kinase-like alpha,Pk428,Rat,Rattus norvegicus,Serine_thre
EIAAB31332 Mouse,Mus musculus,Pkn,Pkn1,Prk1,Prkcl1,Protein kinase C-like 1,Protein kinase C-like PKN,Protein-kinase C-related kinase 1,Serine_threonine-protein kinase N1,Serine-threonine protein kinase N
17-662-20008 Calcium_calmodulin-dependent protein kinase type II alpha chain - EC; CaM-kinase II alpha chain; CaM kinase II alpha subunit; CaMK-II subunit alpha Serum 0.1 ml
18-662-20052 Calcium_calmodulin-dependent protein kinase type II alpha chain - EC; CaM-kinase II alpha chain; CaM kinase II alpha subunit; CaMK-II subunit alpha Polyclonal 0.1 ml
EIAAB31006 Homo sapiens,Human,Phosphatidylinositol 4-kinase alpha,PI4KA,PI4K-alpha,PI4-kinase alpha,PIK4,PIK4CA,PtdIns-4-kinase alpha
18-785-210340 p70 S6 Kinase (Ab-389) - EC; Ribosomal protein S6 kinase I; S6K; S6K1; 70 kDa ribosomal protein S6 kinase 1; p70 S6 kinase alpha; p70(S6K)-alpha; p70-S6K; P70S6K; p70-alpha Polyclonal 0.05 mg
18-785-210343 p70 S6 Kinase (Ab-424) - EC; Ribosomal protein S6 kinase I; S6K; S6K1; 70 kDa ribosomal protein S6 kinase 1; p70 S6 kinase alpha; p70(S6K)-alpha; p70-S6K; P70S6K; p70-alpha Polyclonal 0.05 mg
18-785-210340 p70 S6 Kinase (Ab-389) - EC; Ribosomal protein S6 kinase I; S6K; S6K1; 70 kDa ribosomal protein S6 kinase 1; p70 S6 kinase alpha; p70(S6K)-alpha; p70-S6K; P70S6K; p70-alpha Polyclonal 0.1 mg
18-785-210341 p70 S6 Kinase (Ab-421) - EC; Ribosomal protein S6 kinase I; S6K; S6K1; 70 kDa ribosomal protein S6 kinase 1; p70 S6 kinase alpha; p70(S6K)-alpha; p70-S6K; P70S6K; p70-alpha Polyclonal 0.05 mg
18-785-210342 p70 S6 Kinase (Ab-411) - EC; Ribosomal protein S6 kinase I; S6K; S6K1; 70 kDa ribosomal protein S6 kinase 1; p70 S6 kinase alpha; p70(S6K)-alpha; p70-S6K; P70S6K; p70-alpha Polyclonal 0.05 mg
18-785-210342 p70 S6 Kinase (Ab-411) - EC; Ribosomal protein S6 kinase I; S6K; S6K1; 70 kDa ribosomal protein S6 kinase 1; p70 S6 kinase alpha; p70(S6K)-alpha; p70-S6K; P70S6K; p70-alpha Polyclonal 0.1 mg
18-785-210343 p70 S6 Kinase (Ab-424) - EC; Ribosomal protein S6 kinase I; S6K; S6K1; 70 kDa ribosomal protein S6 kinase 1; p70 S6 kinase alpha; p70(S6K)-alpha; p70-S6K; P70S6K; p70-alpha Polyclonal 0.1 mg
18-785-210341 p70 S6 Kinase (Ab-421) - EC; Ribosomal protein S6 kinase I; S6K; S6K1; 70 kDa ribosomal protein S6 kinase 1; p70 S6 kinase alpha; p70(S6K)-alpha; p70-S6K; P70S6K; p70-alpha Polyclonal 0.1 mg
EIAAB24858 c-Jun N-terminal kinase 2,Jnk2,MAP kinase 9,MAPK 9,Mapk9,Mitogen-activated protein kinase 9,p54-alpha,Prkm9,Rat,Rattus norvegicus,SAPK-alpha,Stress-activated protein kinase JNK2
EIAAB31007 Bos taurus,Bovine,Phosphatidylinositol 4-kinase alpha,PI4KA,PI4K-alpha,PI4-kinase alpha,PIK4CA,PtdIns-4-kinase alpha
EIAAB11059 80 kDa diacylglycerol kinase,DAG kinase alpha,DAGK,DAGK1,DGKA,DGK-alpha,Diacylglycerol kinase alpha,Diglyceride kinase alpha,Homo sapiens,Human

https://antibody-antibodies.com/ | https://gentaur.com/ | https://gen-script.com/ | https://diagenox.com/ | https://clonagen.com/ | http://gentaursearch.com/ | http://gentaurpub.com/ | https://gentaur-online.com/ | http://anti-anti-pdf.com/ | http://gentaur-worldwide.com/


GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur | Gentaur

Unicorn House, Station Cl
Hertfordshire, Potters Bar EN6 1TL
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur | Gentaur



9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017
RIB 30004 00187 00010092253 10
IBAN FR76 3000 4001 8700 0100 9225 310
france@gentaur.com | Gentaur | Gentaur

Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: +49 0241 40 08 90 86, +49 0241 95 78 94 78, +49 0241 40 08 90 86
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur | Gentaur

Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123

GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U

spain@gentaur.com | Gentaur | Gentaur

ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur | Gentaur
IBAN: BG11FINV91501014771636

GENTAUR Poland Sp. z o.o.

ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556


Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur | Gentaur